| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alzheimer Disease | 24 | 2020 | 280 | 2.240 |
Why?
|
| Cognition | 21 | 2020 | 547 | 1.810 |
Why?
|
| Growth Hormone-Releasing Hormone | 4 | 2018 | 7 | 1.010 |
Why?
|
| Neuropsychological Tests | 22 | 2019 | 327 | 0.920 |
Why?
|
| Insulin | 12 | 2015 | 359 | 0.920 |
Why?
|
| Postmenopause | 7 | 2019 | 424 | 0.900 |
Why?
|
| Exercise | 8 | 2019 | 603 | 0.840 |
Why?
|
| Cognition Disorders | 8 | 2013 | 349 | 0.810 |
Why?
|
| Exercise Therapy | 4 | 2020 | 250 | 0.790 |
Why?
|
| Hormones | 2 | 2013 | 24 | 0.770 |
Why?
|
| Glucose | 4 | 2013 | 160 | 0.750 |
Why?
|
| Insulin Resistance | 7 | 2019 | 458 | 0.730 |
Why?
|
| Aged | 48 | 2019 | 10260 | 0.690 |
Why?
|
| Peptide Fragments | 8 | 2018 | 414 | 0.630 |
Why?
|
| Cacao | 1 | 2019 | 4 | 0.610 |
Why?
|
| Aged, 80 and over | 26 | 2019 | 3898 | 0.600 |
Why?
|
| Estradiol | 3 | 2011 | 139 | 0.590 |
Why?
|
| Female | 53 | 2019 | 19942 | 0.590 |
Why?
|
| Double-Blind Method | 16 | 2019 | 565 | 0.590 |
Why?
|
| Hypovolemia | 1 | 2018 | 3 | 0.580 |
Why?
|
| Phlebotomy | 1 | 2018 | 14 | 0.580 |
Why?
|
| Vitamins | 1 | 2019 | 71 | 0.580 |
Why?
|
| Plant Extracts | 1 | 2019 | 61 | 0.580 |
Why?
|
| Erythrocyte Transfusion | 1 | 2018 | 27 | 0.570 |
Why?
|
| Blood Loss, Surgical | 1 | 2018 | 50 | 0.570 |
Why?
|
| Hepatectomy | 1 | 2018 | 57 | 0.560 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2019 | 1437 | 0.560 |
Why?
|
| Dietary Supplements | 1 | 2019 | 188 | 0.540 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 5 | 2019 | 54 | 0.530 |
Why?
|
| Humans | 63 | 2020 | 32274 | 0.520 |
Why?
|
| Brain | 7 | 2017 | 965 | 0.520 |
Why?
|
| Male | 46 | 2019 | 19437 | 0.510 |
Why?
|
| Life Style | 6 | 2020 | 393 | 0.480 |
Why?
|
| Middle Aged | 31 | 2019 | 11848 | 0.480 |
Why?
|
| Memory | 8 | 2018 | 202 | 0.470 |
Why?
|
| Apolipoprotein E4 | 9 | 2015 | 56 | 0.470 |
Why?
|
| Hypoglycemic Agents | 6 | 2015 | 186 | 0.440 |
Why?
|
| Follow-Up Studies | 11 | 2018 | 2240 | 0.420 |
Why?
|
| Aging | 5 | 2013 | 942 | 0.420 |
Why?
|
| Dementia | 6 | 2020 | 246 | 0.410 |
Why?
|
| Sleep | 5 | 2019 | 84 | 0.380 |
Why?
|
| Osteoarthritis | 4 | 2014 | 73 | 0.380 |
Why?
|
| Glucose Intolerance | 2 | 2010 | 40 | 0.370 |
Why?
|
| Estrogens | 2 | 2011 | 194 | 0.360 |
Why?
|
| Diet, Fat-Restricted | 1 | 2012 | 28 | 0.360 |
Why?
|
| Hydrocortisone | 1 | 2011 | 61 | 0.340 |
Why?
|
| Executive Function | 5 | 2019 | 52 | 0.330 |
Why?
|
| Physical Fitness | 2 | 2010 | 120 | 0.310 |
Why?
|
| Prediabetic State | 1 | 2010 | 76 | 0.310 |
Why?
|
| Motor Activity | 1 | 2012 | 332 | 0.300 |
Why?
|
| Cerebral Cortex | 1 | 2010 | 143 | 0.300 |
Why?
|
| Lipid Metabolism | 3 | 2015 | 108 | 0.290 |
Why?
|
| Overweight | 4 | 2018 | 252 | 0.270 |
Why?
|
| Time Factors | 7 | 2019 | 2204 | 0.260 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2011 | 216 | 0.250 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2012 | 85 | 0.250 |
Why?
|
| Treatment Outcome | 15 | 2019 | 3416 | 0.250 |
Why?
|
| Hormone Replacement Therapy | 2 | 2017 | 94 | 0.240 |
Why?
|
| Affect | 3 | 2012 | 70 | 0.200 |
Why?
|
| Residence Characteristics | 2 | 2015 | 178 | 0.180 |
Why?
|
| Caloric Restriction | 2 | 2019 | 92 | 0.170 |
Why?
|
| Longitudinal Studies | 7 | 2019 | 757 | 0.170 |
Why?
|
| Absorptiometry, Photon | 2 | 2012 | 98 | 0.170 |
Why?
|
| Analysis of Variance | 5 | 2015 | 471 | 0.170 |
Why?
|
| Obesity | 5 | 2019 | 1111 | 0.170 |
Why?
|
| Sulfonamides | 3 | 2011 | 86 | 0.160 |
Why?
|
| Diet | 2 | 2013 | 383 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2011 | 66 | 0.160 |
Why?
|
| Risk Factors | 4 | 2018 | 3934 | 0.160 |
Why?
|
| Problem Solving | 2 | 2018 | 25 | 0.160 |
Why?
|
| Genotype | 5 | 2013 | 702 | 0.150 |
Why?
|
| Central Venous Pressure | 1 | 2018 | 5 | 0.150 |
Why?
|
| Amnesia | 2 | 2011 | 5 | 0.150 |
Why?
|
| Gyrus Cinguli | 2 | 2016 | 26 | 0.140 |
Why?
|
| Colorectal Surgery | 1 | 2018 | 2 | 0.140 |
Why?
|
| Research Design | 3 | 2020 | 314 | 0.140 |
Why?
|
| Estrogens, Conjugated (USP) | 2 | 2017 | 157 | 0.140 |
Why?
|
| Cohort Studies | 7 | 2018 | 1840 | 0.140 |
Why?
|
| Killer Cells, Natural | 1 | 2018 | 21 | 0.140 |
Why?
|
| Interferon-gamma | 1 | 2018 | 59 | 0.140 |
Why?
|
| Heart Rate | 2 | 2010 | 362 | 0.130 |
Why?
|
| Dietary Fats | 2 | 2015 | 99 | 0.130 |
Why?
|
| Liver Neoplasms | 1 | 2018 | 164 | 0.130 |
Why?
|
| Nootropic Agents | 1 | 2017 | 13 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 541 | 0.130 |
Why?
|
| Decision Making | 1 | 2018 | 189 | 0.120 |
Why?
|
| Risk Reduction Behavior | 2 | 2020 | 117 | 0.120 |
Why?
|
| Retrospective Studies | 3 | 2018 | 3624 | 0.120 |
Why?
|
| West Nile virus | 1 | 2016 | 2 | 0.120 |
Why?
|
| West Nile Fever | 1 | 2016 | 2 | 0.120 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 219 | 0.120 |
Why?
|
| Glucose Tolerance Test | 2 | 2015 | 126 | 0.120 |
Why?
|
| Geriatric Assessment | 1 | 2018 | 335 | 0.120 |
Why?
|
| Positron-Emission Tomography | 3 | 2014 | 171 | 0.120 |
Why?
|
| Behavior Therapy | 1 | 2017 | 102 | 0.120 |
Why?
|
| Apolipoproteins E | 5 | 2014 | 87 | 0.120 |
Why?
|
| Polysomnography | 1 | 2016 | 39 | 0.120 |
Why?
|
| Memory Disorders | 2 | 2008 | 49 | 0.120 |
Why?
|
| Retinal Diseases | 1 | 2016 | 25 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 46 | 0.120 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 56 | 0.110 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2015 | 3 | 0.110 |
Why?
|
| Prefrontal Cortex | 1 | 2016 | 85 | 0.110 |
Why?
|
| Housing | 1 | 2015 | 35 | 0.110 |
Why?
|
| Dexamethasone | 1 | 2015 | 46 | 0.110 |
Why?
|
| Insulin, Long-Acting | 1 | 2015 | 3 | 0.110 |
Why?
|
| Case-Control Studies | 2 | 2018 | 854 | 0.110 |
Why?
|
| Pain | 2 | 2014 | 303 | 0.110 |
Why?
|
| Body Mass Index | 5 | 2019 | 863 | 0.110 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2015 | 38 | 0.110 |
Why?
|
| Ankle Brachial Index | 1 | 2014 | 38 | 0.110 |
Why?
|
| Cerebellar Diseases | 1 | 2014 | 4 | 0.110 |
Why?
|
| Cerebellar Cortex | 1 | 2014 | 4 | 0.110 |
Why?
|
| Laminin | 1 | 2014 | 13 | 0.110 |
Why?
|
| Amyloid | 1 | 2014 | 16 | 0.110 |
Why?
|
| Naproxen | 2 | 2011 | 7 | 0.110 |
Why?
|
| Cysts | 1 | 2014 | 17 | 0.110 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 99 | 0.110 |
Why?
|
| Primary Health Care | 2 | 2014 | 232 | 0.110 |
Why?
|
| Commerce | 1 | 2015 | 69 | 0.110 |
Why?
|
| Sex Characteristics | 2 | 2013 | 173 | 0.100 |
Why?
|
| Pyrazoles | 2 | 2011 | 77 | 0.100 |
Why?
|
| Fatigue | 1 | 2014 | 76 | 0.100 |
Why?
|
| Mental Status Schedule | 4 | 2017 | 21 | 0.100 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2011 | 52 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 717 | 0.100 |
Why?
|
| Exercise Test | 2 | 2016 | 217 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2018 | 823 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2018 | 1425 | 0.100 |
Why?
|
| Arthralgia | 1 | 2013 | 29 | 0.100 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 82 | 0.100 |
Why?
|
| Patient Selection | 1 | 2014 | 272 | 0.090 |
Why?
|
| Psychotherapy, Group | 1 | 2012 | 15 | 0.090 |
Why?
|
| Mental Recall | 3 | 2015 | 47 | 0.090 |
Why?
|
| Administration, Intranasal | 4 | 2015 | 35 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 120 | 0.090 |
Why?
|
| Prevalence | 4 | 2019 | 955 | 0.090 |
Why?
|
| Severity of Illness Index | 4 | 2012 | 853 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 22 | 0.090 |
Why?
|
| Radioimmunoassay | 1 | 2011 | 25 | 0.090 |
Why?
|
| Neuropeptides | 1 | 2011 | 23 | 0.090 |
Why?
|
| Food, Formulated | 1 | 2011 | 13 | 0.090 |
Why?
|
| Dietary Carbohydrates | 1 | 2011 | 21 | 0.090 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2011 | 28 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2013 | 255 | 0.080 |
Why?
|
| Body Composition | 1 | 2012 | 327 | 0.080 |
Why?
|
| Energy Metabolism | 2 | 2010 | 153 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2014 | 861 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2010 | 94 | 0.080 |
Why?
|
| Thromboxane B2 | 1 | 2010 | 5 | 0.080 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2010 | 3 | 0.080 |
Why?
|
| Glucose Clamp Technique | 1 | 2010 | 6 | 0.080 |
Why?
|
| Body Fat Distribution | 1 | 2010 | 25 | 0.080 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2010 | 37 | 0.080 |
Why?
|
| Brain Chemistry | 2 | 2013 | 46 | 0.080 |
Why?
|
| Patient Education as Topic | 3 | 2017 | 245 | 0.080 |
Why?
|
| Anticholesteremic Agents | 1 | 2010 | 47 | 0.070 |
Why?
|
| tau Proteins | 3 | 2017 | 39 | 0.070 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2017 | 83 | 0.070 |
Why?
|
| Oxygen Consumption | 1 | 2010 | 141 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2010 | 73 | 0.070 |
Why?
|
| Octreotide | 1 | 2009 | 6 | 0.070 |
Why?
|
| Gastrointestinal Agents | 1 | 2009 | 6 | 0.070 |
Why?
|
| Somatostatin | 1 | 2009 | 11 | 0.070 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 119 | 0.070 |
Why?
|
| Norepinephrine | 2 | 2006 | 101 | 0.070 |
Why?
|
| Verbal Behavior | 1 | 2008 | 7 | 0.070 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 167 | 0.070 |
Why?
|
| Administration, Cutaneous | 2 | 2011 | 116 | 0.070 |
Why?
|
| Cloprostenol | 1 | 2007 | 1 | 0.070 |
Why?
|
| Thiazines | 1 | 2007 | 1 | 0.070 |
Why?
|
| Exfoliation Syndrome | 1 | 2007 | 2 | 0.070 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2007 | 2 | 0.070 |
Why?
|
| Ocular Hypertension | 1 | 2007 | 9 | 0.070 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 1479 | 0.070 |
Why?
|
| Quinoxalines | 1 | 2007 | 13 | 0.060 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2007 | 22 | 0.060 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2007 | 43 | 0.060 |
Why?
|
| Memory, Short-Term | 2 | 2019 | 61 | 0.060 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2006 | 16 | 0.060 |
Why?
|
| Health Status | 2 | 2019 | 355 | 0.060 |
Why?
|
| Organ Size | 2 | 2017 | 221 | 0.060 |
Why?
|
| Hyperinsulinism | 1 | 2005 | 13 | 0.060 |
Why?
|
| Regression Analysis | 2 | 2019 | 273 | 0.060 |
Why?
|
| Thiazolidinediones | 1 | 2005 | 46 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2018 | 2316 | 0.060 |
Why?
|
| Activities of Daily Living | 2 | 2017 | 245 | 0.060 |
Why?
|
| Area Under Curve | 2 | 2015 | 90 | 0.050 |
Why?
|
| Cytokines | 1 | 2005 | 237 | 0.050 |
Why?
|
| 3-Hydroxybutyric Acid | 1 | 2004 | 2 | 0.050 |
Why?
|
| Aptitude | 1 | 2004 | 2 | 0.050 |
Why?
|
| Automobile Driving | 1 | 2004 | 25 | 0.050 |
Why?
|
| Smoking | 2 | 2019 | 505 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2003 | 7 | 0.050 |
Why?
|
| Alleles | 2 | 2014 | 250 | 0.050 |
Why?
|
| Triglycerides | 1 | 2004 | 235 | 0.050 |
Why?
|
| Adult | 5 | 2016 | 9256 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 276 | 0.050 |
Why?
|
| Inflammation | 1 | 2005 | 506 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 1158 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2020 | 312 | 0.040 |
Why?
|
| Neuroprotective Agents | 1 | 2002 | 32 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 2002 | 104 | 0.040 |
Why?
|
| Pain Measurement | 2 | 2013 | 341 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 1223 | 0.040 |
Why?
|
| United States | 3 | 2016 | 4072 | 0.040 |
Why?
|
| Attention | 2 | 2014 | 84 | 0.040 |
Why?
|
| Verbal Learning | 1 | 2019 | 7 | 0.040 |
Why?
|
| Indians, North American | 1 | 2019 | 75 | 0.040 |
Why?
|
| Age Factors | 2 | 2016 | 1179 | 0.040 |
Why?
|
| Cerebrovascular Disorders | 1 | 2019 | 51 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 489 | 0.040 |
Why?
|
| Young Adult | 2 | 2016 | 2648 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2019 | 456 | 0.030 |
Why?
|
| Synaptotagmins | 1 | 2018 | 1 | 0.030 |
Why?
|
| Synaptophysin | 1 | 2018 | 2 | 0.030 |
Why?
|
| F2-Isoprostanes | 2 | 2010 | 20 | 0.030 |
Why?
|
| Animals | 4 | 2015 | 8199 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 292 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 125 | 0.030 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 556 | 0.030 |
Why?
|
| Exosomes | 1 | 2018 | 43 | 0.030 |
Why?
|
| Pilot Projects | 2 | 2011 | 553 | 0.030 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2017 | 112 | 0.030 |
Why?
|
| Disease Progression | 1 | 2019 | 591 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2017 | 194 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 757 | 0.030 |
Why?
|
| Oximetry | 1 | 2016 | 32 | 0.030 |
Why?
|
| Social Support | 1 | 2017 | 180 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 1241 | 0.030 |
Why?
|
| Residential Facilities | 1 | 2015 | 1 | 0.030 |
Why?
|
| Housing for the Elderly | 1 | 2015 | 3 | 0.030 |
Why?
|
| Lymphocyte Depletion | 1 | 2015 | 18 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2015 | 11 | 0.030 |
Why?
|
| Ownership | 1 | 2015 | 13 | 0.030 |
Why?
|
| Financing, Government | 1 | 2015 | 11 | 0.030 |
Why?
|
| Self Care | 1 | 2016 | 97 | 0.030 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2015 | 37 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2015 | 34 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2015 | 59 | 0.030 |
Why?
|
| Psychomotor Disorders | 1 | 2015 | 5 | 0.030 |
Why?
|
| Radiography | 1 | 2016 | 362 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 196 | 0.030 |
Why?
|
| Space Perception | 1 | 2015 | 30 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 308 | 0.030 |
Why?
|
| Muscular Dystrophies | 1 | 2014 | 3 | 0.030 |
Why?
|
| Disabled Persons | 1 | 2015 | 100 | 0.030 |
Why?
|
| Mice | 2 | 2015 | 2571 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2014 | 18 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 36 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 132 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 1534 | 0.030 |
Why?
|
| Base Sequence | 1 | 2014 | 252 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2014 | 85 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2015 | 454 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 410 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2014 | 132 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 555 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2013 | 36 | 0.020 |
Why?
|
| Cholesterol | 1 | 2015 | 262 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 2013 | 35 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2013 | 93 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 743 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 120 | 0.020 |
Why?
|
| Smoking Cessation | 1 | 2015 | 211 | 0.020 |
Why?
|
| Blood Glucose | 2 | 2006 | 484 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2012 | 25 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 316 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2012 | 77 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 883 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2011 | 32 | 0.020 |
Why?
|
| Immunoassay | 1 | 2011 | 16 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2011 | 22 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2011 | 44 | 0.020 |
Why?
|
| North Carolina | 1 | 2015 | 1300 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 1083 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 141 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 323 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2014 | 1233 | 0.020 |
Why?
|
| Aspirin | 1 | 2010 | 59 | 0.020 |
Why?
|
| Homeostasis | 1 | 2010 | 130 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 773 | 0.020 |
Why?
|
| Acetylcholine | 1 | 2009 | 69 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 3517 | 0.020 |
Why?
|
| Child | 1 | 2014 | 2434 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 2007 | 41 | 0.020 |
Why?
|
| Circadian Rhythm | 1 | 2007 | 46 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 390 | 0.020 |
Why?
|
| Japan | 1 | 2006 | 19 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 99 | 0.010 |
Why?
|
| Prealbumin | 1 | 2005 | 8 | 0.010 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2006 | 101 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2005 | 48 | 0.010 |
Why?
|
| PPAR gamma | 1 | 2005 | 51 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2005 | 224 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2005 | 215 | 0.010 |
Why?
|
| Ketone Bodies | 1 | 2004 | 7 | 0.010 |
Why?
|
| Mental Competency | 1 | 2004 | 11 | 0.010 |
Why?
|
| Language | 1 | 2004 | 36 | 0.010 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2003 | 3 | 0.010 |
Why?
|
| Homozygote | 1 | 2003 | 52 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2003 | 73 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 92 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 109 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2004 | 108 | 0.010 |
Why?
|
| Prostate | 1 | 2003 | 88 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2003 | 132 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 454 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 543 | 0.010 |
Why?
|
| Cerebrovascular Circulation | 1 | 2002 | 93 | 0.010 |
Why?
|